-
$21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
-
Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
-
Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability
BlueCube Bio Becomes Evia Bio™ and Launches iPSC Cryopreservation Solution for Cell & Gene Therapies
MINNEAPOLIS, Dec. 9, 2021 — BlueCube Bio officially announced a company name transition to Evia Bio™, concurrent with the launch of a significant new cryopreservation technology for use in cell and gene therapies utilizing Induced Pluripotent Stem Cells (iPSCs). The osmolyte-based solution increases cell survival above that of commercially available DMSO-based options which is critical for realizing the potential of these therapies. This latest addition expands the company’s portfolio of patented cryopreservation products that also include products for mesenchymal stem cells (MSCs). [Read more…]
Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings
Ncardia forms strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services
November 16, 2021, GOSSELIES, Belgium & NEW YORK — Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide. [Read more…]
Shoreline Biosciences Announces $140M Financing To Advance Pipeline of iPSC-based Cell Immunotherapies
-
Shoreline Biosciences Announces $140M Financing To Advance Its Growing Pipeline Of Next Generation Cell Immunotherapies
-
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities.
Curi Bio and NEXEL Form Celogics, a Joint Venture to Develop iPSC-Derived Products
Celogics, based in Seattle, will offer high-quality iPSC-derived cell products for drug discovery and safety testing.
OCTOBER 26, 2021, SEATTLE and SEOUL – Curi Bio, a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, today announced the formation of Celogics, a joint venture company focused on the development and commercialization of human iPSC-derived cell products for drug discovery, drug safety testing, and biological research. Celogics iPSC production and distribution headquarters will be located in Seattle, WA. [Read more…]
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 79
- Next Page »